Suggested remit: To appraise the clinical and cost effectiveness of sodium thiosulfate within its marketing authorisation for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy.
 
Status In progress
Decision Selected
Process STA 2018
ID number 1001

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
22 January 2021 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of sodium thiosulfate within its marketing authorisation for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy. Please note that following advice received from the company the timelines for this appraisal are to be confirmed. We hope to have a further update for you in due course.
22 January 2021 In progress. Topic is in progress
11 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
23 January 2020 - 20 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual